Anda belum login :: 23 Jul 2025 06:47 WIB
Home
|
Logon
Hidden
»
Administration
»
Collection Detail
Detail
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporos
Oleh:
Black, Dennis M.
;
Delmas, Pierre D
;
Eastell, Richard
;
Boonen, Steven
;
Cauley, Jane A.
;
Cosman, Felicia
;
Leung, Ping Chung
;
Man, Zulema
;
Mautalen, Carlos
;
Mesenbrink, Peter
;
Caminis, John
;
Tong, Karen
;
Rosario-jansen, Theresa
;
Krasnow, Joel
;
Sellmeyer, Deborah
;
Fink Eriksen, Erik
;
Cummings, Steven R.
Jenis:
Article from Journal - ilmiah internasional
Dalam koleksi:
The New England Journal of Medicine (keterangan: ada di Proquest) vol. 356 no. 18 (May 2007)
,
page 1809.
Ketersediaan
Perpustakaan FK
Nomor Panggil:
N08.K.2007.03
Non-tandon:
1 (dapat dipinjam: 0)
Tandon:
tidak ada
Lihat Detail Induk
Isi artikel
BACKGROUND A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed I the effects of annual infusions of zoledronic acid on fracture risk during a 3-year : period. METHODS In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single IS-minute infusion of zoledronic acid (5 mg) I and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral: fracture (in patients not taking concomitant osteoporosis medications) and hip frac- ! ture (in all patients). Secondary end points included bone mineral density, bone turn-over markers, and safety outcomes. RESULTS Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], ( 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid B group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Non- ~ vertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by s 25%, 33%, and 77%, respectively (P
Opini Anda
Klik untuk menuliskan opini Anda tentang koleksi ini!
Kembali
Process time: 0.015625 second(s)